Modulating Mitofusins to Enhance Therapeutic T Cell Expansion and Persistence
1 of 4
Graft versus Host Disease and Donor T cell Activation Is Limited by Vasoactive Intestinal Peptide Synthesis by Host Non-hempatopoietic Cells
2 of 4
Vasoactive Intestinal Peptide Antagonist Enhances T cell Proliferation and Synergizes with PD-1 Antibodies to Promote Anti-Melanoma T cell Immune Responses
3 of 4
Antagonism of the vasoactive intestinal peptide and PI3K δ signaling pathways in T cell-based therapies for leukemia and lymphoma